What it's for (Indications)
- Nalidixic acid is an antibacterial agent indicated for the treatment of acute and chronic urinary tract infections (UTIs) caused by susceptible gram-negative microorganisms.
- These typically include strains of *Escherichia coli*, *Proteus* species (e.
- g.
- , *P.
- mirabilis*, *P.
- morganii*, *P.
- vulgaris*), *Klebsiella* species, and *Enterobacter* species.
- It is important to note that nalidixic acid is generally not effective against gram-positive organisms or *Pseudomonas aeruginosa*.
- This medication is specifically reserved for infections confined to the urinary tract and is not intended for systemic infections, given its pharmacokinetic profile and spectrum of activity.
- Appropriate microbiological cultures and susceptibility testing should be performed prior to and periodically during therapy to confirm the susceptibility of the causative organisms.
- The decision to use nalidixic acid should consider its narrow spectrum, potential for resistance, and the availability of alternative agents.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For adults, the typical recommended oral dosage of nalidixic acid is 1 gram administered four times daily (every 6 hours) for a duration of one to two weeks, depending on the severity of the infection and clinical response. In pediatric patients aged 3 months and older, the dosage is calculated based on body weight, usually 55 mg/kg per day, divided into four equal doses. For prolonged therapy or suppression of chronic infections in children, the dosage may be reduced to 33 mg/kg per day, divided into four doses. It is crucial to administer the full prescribed course of treatment, even if symptoms improve, to minimize the risk of bacterial resistance and relapse. Dosage adjustments may be necessary in patients with impaired renal function; however, its use is generally contraindicated in severe renal impairment. Administration with food may help reduce gastrointestinal upset and should be encouraged. |
Safety & Warnings
Common Side Effects
- Nalidixic acid can cause a range of adverse effects.
- Common gastrointestinal disturbances include nausea, vomiting, diarrhea, and abdominal discomfort.
- Central nervous system (CNS) effects are also frequently reported and may include headache, dizziness, drowsiness, confusion, and visual disturbances, such as sensitivity to light, changes in color perception, or double vision.
- Dermatological reactions, including skin rash, pruritus, and significant photosensitivity, are known; patients should be advised to avoid excessive sun exposure.
- More serious, though less common, adverse reactions include convulsions (seizures), increased intracranial pressure (pseudotumor cerebri), and psychosis.
- Hematologic effects such as hemolytic anemia (particularly in patients with G6PD deficiency), leukopenia, thrombocytopenia, and eosinophilia have been observed.
- Hepatic dysfunction, including cholestasis, may also occur.
- Any severe or persistent side effects, including sudden onset of visual changes or neurological symptoms, should be reported to a healthcare professional immediately for evaluation.
Serious Warnings
- Black Box Warning: **Serious Warnings:** While nalidixic acid does not carry a formal FDA-mandated Black Box Warning similar to later-generation fluoroquinolones, it is associated with significant and potentially severe adverse reactions that warrant explicit caution and careful patient selection. These serious risks are critical considerations for safe prescribing: **Neurological Toxicity:** Nalidixic acid can cause severe central nervous system (CNS) effects, including convulsions (seizures), increased intracranial pressure (pseudotumor cerebri), and psychosis. These effects can occur even at therapeutic doses and are more likely in patients with pre-existing CNS disorders, severe atherosclerosis, or inadequate cerebral circulation. Discontinuation of the drug is usually warranted if these symptoms arise, and they typically resolve upon cessation of therapy. **Photosensitivity:** Severe photosensitivity reactions have been reported, manifesting as exaggerated sunburn upon exposure to sunlight or artificial ultraviolet light. Patients must be strongly advised to avoid direct sun exposure and artificial UV light and to use protective clothing and broad-spectrum sunscreen with a high SPF to mitigate this risk. **Hemolytic Anemia:** In patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, nalidixic acid can induce hemolytic anemia, which may be severe and require immediate medical intervention. This necessitates careful screening and monitoring in at-risk populations. **Cartilage Damage in Juveniles:** Although less prominently highlighted for nalidixic acid specifically than for newer fluoroquinolones, the quinolone class has been associated with arthropathy and cartilage damage in immature animals. Consequently, nalidixic acid is contraindicated in infants under 3 months of age, and caution is advised in pediatric populations, weighing the benefits against potential risks to musculoskeletal development. Healthcare providers must thoroughly evaluate patient risk factors before prescribing and educate patients on these critical safety concerns.
- Nalidixic acid should be used with extreme caution in patients with a history of convulsive disorders, epilepsy, or other predisposing factors for seizures, as it can lower the seizure threshold and precipitate convulsions.
- Increased intracranial pressure with bulging fontanelles in infants and pseudotumor cerebri have been reported; these manifestations usually resolve quickly upon discontinuation of the drug.
- Photosensitivity reactions can be severe; patients must be advised to avoid direct sunlight and artificial UV light and to use protective clothing and sunscreen with high SPF to prevent severe burns.
- Hemolytic anemia, sometimes severe, has been associated with nalidixic acid therapy, particularly in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency; close monitoring is advised in this population.
- Long-term use or higher doses may lead to the emergence of resistant organisms.
- This medication is not recommended for infants under 3 months of age due to potential effects on cartilage development, although robust clinical evidence for this specific agent is less than for newer fluoroquinolones.
- Patients should be adequately hydrated to prevent crystalluria.
- Antagonism between nalidixic acid and nitrofurantoin has been observed in vitro; concurrent use is therefore not recommended.
- Nalidixic acid may potentiate the effects of oral anticoagulants like warfarin, necessitating careful monitoring of prothrombin time and INR.
How it Works (Mechanism of Action)
Nalidixic acid belongs to the quinolone class of antimicrobials, specifically classified as a first-generation quinolone or a naphthyridone. Its bactericidal action is achieved by inhibiting essential bacterial enzymes responsible for DNA replication and repair. The primary targets are bacterial DNA gyrase (also known as topoisomerase II) and topoisomerase IV. These enzymes are critical for supercoiling and uncoiling bacterial DNA, which is essential for processes like DNA replication, transcription, and recombination. By binding to and interfering with the function of these enzymes, nalidixic acid causes breaks in the bacterial DNA strands, leading to a disruption of cellular functions and ultimately bacterial cell death. This selective inhibition primarily affects susceptible gram-negative bacteria that are active in DNA synthesis, providing its therapeutic utility in urinary tract infections where such organisms are commonly causative agents.
Commercial Brands (Alternatives)
No other brands found for this formula.